Pharmacogenetics is the study of how interindividual variations in the DNA sequence of
specific genes affect drug response. This article highlights current pharmacogenetic …

Variability of drug metabolism, especially that of the most important phase I enzymes or
cytochrome P450 (CYP) enzymes, is an important complicating factor in many areas of …

Organic fluorine compounds have had a profound impact on the development of bioactives
for the modern pharmaceuticals market. It is estimated that up to 20% of pharmaceuticals …

Proton pump inhibitors (PPIs) have become some of the most frequently prescribed
medications for treatment of adults and children. Their effectiveness for treatment of peptic …

Cytochrome P450 2C9 (CYP2C9) is one of the most abundant CYP enzymes in the human
liver. CYP2C9 metabolizes more than 100 therapeutic drugs, including tolbutamide …

The dramatic success of pharmacological acid suppression in healing peptic ulcers and
managing patients with gastroesophageal reflux disease (GERD) has been reflected in the …

The use of proton pump inhibitors (PPIs) has become widespread in children and infants for
the management of paediatric acid-related disease. Pharmacokinetic profiles of only …

Abnormally aggregated tau is the hallmark pathology of tauopathy neurodegenerative
disorders and is a target for development of both diagnostic tools and therapeutic strategies …

Cytochromes P450 (P450s or CYPs) are the most important phase I metabolic enzymes in
the human body and are responsible for metabolizing∼ 75% of the clinically used drugs …

Human CYP2C8 is a key member of the CYP2C family and metabolizes more than 60
clinical drugs. A number of active site residues in CYP2C8 have been identified based on …